QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

$56.95
-0.17 (-0.30%)
(As of 09:58 AM ET)
Today's Range
$56.82
$57.40
50-Day Range
$56.55
$61.87
52-Week Range
$50.27
$76.04
Volume
112,283 shs
Average Volume
1.71 million shs
Market Capitalization
$12.79 billion
P/E Ratio
21.49
Dividend Yield
N/A
Price Target
$76.07

Incyte MarketRank™ Stock Analysis

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
33.2% Upside
$76.07 Price Target
Short Interest
Bearish
3.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.97mentions of Incyte in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$42,705 Sold Last Quarter
Proj. Earnings Growth
25.19%
From $3.85 to $4.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

13th out of 939 stocks

Commercial Physical Research Industry

1st out of 11 stocks

INCY stock logo

About Incyte Stock (NASDAQ:INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Stock Price History

INCY Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
5 Biotech Stocks with Huge Potential
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
Incyte: A Potential GARP Superstar
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,524
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$76.07
High Stock Price Target
$93.00
Low Stock Price Target
$64.00
Potential Upside/Downside
+33.2%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$597.60 million
Pretax Margin
22.57%

Debt

Sales & Book Value

Annual Sales
$3.70 billion
Cash Flow
$2.46 per share
Book Value
$23.16 per share

Miscellaneous

Free Float
185,234,000
Market Cap
$12.83 billion
Optionable
Optionable
Beta
0.65

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

INCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price target for 2024?

15 Wall Street research analysts have issued 12-month price targets for Incyte's stock. Their INCY share price targets range from $64.00 to $93.00. On average, they predict the company's share price to reach $76.07 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2024?

Incyte's stock was trading at $62.79 at the beginning of the year. Since then, INCY stock has decreased by 9.0% and is now trading at $57.12.
View the best growth stocks for 2024 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by $0.09. The biopharmaceutical company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Incyte had a trailing twelve-month return on equity of 12.56% and a net margin of 16.17%. Incyte's quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.44 earnings per share.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.05%), Vanguard Group Inc. (10.03%), Dodge & Cox (7.17%), LSV Asset Management (1.20%), Bellevue Group AG (0.96%) and Northern Trust Corp (0.88%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INCY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners